<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03779464</url>
  </required_header>
  <id_info>
    <org_study_id>XHZL-001</org_study_id>
    <nct_id>NCT03779464</nct_id>
  </id_info>
  <brief_title>Study of Gemcitabine Plus Nab-paclitaxel Versus S1 Plus Nab-paclitaxel in Metastatic Adenocarcinoma of the Pancreas</brief_title>
  <official_title>Phase II Study of Gemcitabine Plus Nab-paclitaxel Versus S1 Plus Nab-paclitaxel in Metastatic Adenocarcinoma of the Pancreas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wuhan Union Hospital, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wuhan Union Hospital, China</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized multi-center phase II trial of nab-paclitaxel in combination with gemcitabine
      verus S1 with gemcitabine as first-Line treatment for locally advanced or metastatic
      pancreatic cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase II, open-label randomized, multicenter trial to compare nab-paclitaxel in combination
      with gemcitabine verus S1 with gemcitabine with respect to overall survival, objective tumor
      response rate and Progression Free Survival (PFS) in patients diagnosed with locally advanced
      or metastatic adenocarcinoma of the pancreas.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2019</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>6 month</time_frame>
    <description>progression-free survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>1 year</time_frame>
    <description>overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>6 month</time_frame>
    <description>objective response rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR</measure>
    <time_frame>6 month</time_frame>
    <description>CR+PR+SD was defined as disease control rate (DCR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile :Adverse events of nab-Paclitaxel plus S-1</measure>
    <time_frame>1 year</time_frame>
    <description>Adverse events of nab-Paclitaxel plus S-1</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">132</enrollment>
  <condition>Pancreatic Cancer</condition>
  <condition>Nab-paclitaxel</condition>
  <condition>Gemcitabine</condition>
  <condition>S1</condition>
  <arm_group>
    <arm_group_label>S/nab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nab-paclitaxel 125 mg/m² (D1, D8, q3w) and S-1 (40 mg BID for body surface area &lt; 1.25 m²; 50 mg BID for body surface area of 1.25-1.5 m²; and 60 mg BID for body surface area &gt;1.5 m²; D1-14, q3w)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gem/nab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nab-paclitaxel 125 mg/m² (D1, D8, q3w) and Gemcitabine 1000 mg/m² (D1, D8, q3w)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S1 or Gemcitabine</intervention_name>
    <description>Gemcitabine 1000 mg/m² (D1, D8, q3w) and S-1 (40 mg BID for body surface area &lt; 1.25 m²; 50 mg BID for body surface area of 1.25-1.5 m²; and 60 mg BID for body surface area &gt;1.5 m²; D1-14, q3w)</description>
    <arm_group_label>Gem/nab</arm_group_label>
    <arm_group_label>S/nab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological or cytological confirmation of pancreatic adenocarcinoma

          -  Distant metastatic or unresctable locally advanced diseases

          -  CTScan (or MRI if scanner contraindicated) completed within 3 weeks of the start of
             treatment

          -  At least one lesion measurable by RECIST v1.1 criteria

          -  Life expectancy&gt; 3 months

          -  No previous chemotherapy (adjuvant chemotherapy with gemcitabine authorised if
             administered more than 6 months prior to inclusion)

          -  No previous radiotherapy (unless at least one measurable target lesion outside the
             irradiation zone)

          -  Pain must be monitored before inclusion

          -  18 years &lt; age &lt; 70

          -  Performance status: 0-1

          -  ANC ≥ 1500/mm3, platelets ≥ 100 000/mm3, haemoglobin ≥ 9 g/dL

          -  ASAT (SGOT), ALAT (SGPT) ≤ 2.5 x ULN or ≤ 5 x ULN if liver metastases found

          -  Bilirubin ≤ 1.5 x ULN (patients drained by retrograde technique are includable),

          -  creatinine &lt; 120 μmol/L, or MDRD creatinine clearance &gt; 60 mL/min

          -  Patient information and signature of informed consent

        Exclusion Criteria:

          -  Concurrent other effective treatment (including radiotherapy)

          -  Resectable patients

          -  Allergy history to other drugs in the same class patients with pregnancy or lactation

          -  Known severe internal medical diseases

          -  Abnormal heart function or relevant history of myocardial infarction and severe
             arrhythmia

          -  Immunocompromised patients, such as HIV positive

          -  Uncontrollable mental illness

          -  Other conditions the researchers considered ineligible for the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zhenyu lin, MD</last_name>
    <phone>86-27-85871982</phone>
    <email>whxhlzy@hust.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tao Zhang, MD</last_name>
    <phone>86-27-85871982</phone>
    <email>taozhangxh@hust.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yu Hu, MD</last_name>
      <phone>027-85726114</phone>
      <email>284409937@qq.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013 Oct 31;369(18):1691-703. doi: 10.1056/NEJMoa1304369. Epub 2013 Oct 16.</citation>
    <PMID>24131140</PMID>
  </results_reference>
  <results_reference>
    <citation>Ueno H, Ioka T, Ikeda M, Ohkawa S, Yanagimoto H, Boku N, Fukutomi A, Sugimori K, Baba H, Yamao K, Shimamura T, Sho M, Kitano M, Cheng AL, Mizumoto K, Chen JS, Furuse J, Funakoshi A, Hatori T, Yamaguchi T, Egawa S, Sato A, Ohashi Y, Okusaka T, Tanaka M. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol. 2013 May 1;31(13):1640-8. doi: 10.1200/JCO.2012.43.3680. Epub 2013 Apr 1.</citation>
    <PMID>23547081</PMID>
  </results_reference>
  <results_reference>
    <citation>Xu Y, Guo X, Fan Y, Wang D, Wu W, Wu L, Liu T, Xu B, Feng Y, Wang Y, Lou W, Zhou Y. Efficacy and safety comparison of nabpaclitaxel plus S-1 and gemcitabine plus S-1 as first-line chemotherapy for metastatic pancreatic cancer. Jpn J Clin Oncol. 2018 Jun 1;48(6):535-541. doi: 10.1093/jjco/hyy063.</citation>
    <PMID>29718363</PMID>
  </results_reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>December 17, 2018</study_first_submitted>
  <study_first_submitted_qc>December 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2018</study_first_posted>
  <last_update_submitted>July 4, 2019</last_update_submitted>
  <last_update_submitted_qc>July 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wuhan Union Hospital, China</investigator_affiliation>
    <investigator_full_name>Tao Zhang</investigator_full_name>
    <investigator_title>Chief of Gastrointestinal Oncology</investigator_title>
  </responsible_party>
  <keyword>pancreatic cancer</keyword>
  <keyword>nab-paclitaxel</keyword>
  <keyword>gemcitabine</keyword>
  <keyword>S1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

